Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2): 635-641.
2.
Eckman MH, Beshansky JR, Durand-Zaleski I, Levine HJ, Pauker SG. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves. Does low risk mean high cost?JAMA. 1990;263(11): 1513-1521.
3.
Dunn AS, Wisnivesky J, Ho W, Moore C, McGinn T, Sacks HS. Perioperative management of patients on oral anticoagulants: A decision analysis. Med Decis Making. 2005;25: 387-397.
4.
Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003;163(8): 901-908.
5.
Ansell JE. The perioperative management of warfarin therapy. Arch Intern Med. 2003;163(8): 881-883.
6.
Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336(21): 1506-1511.
7.
Lowson SM, Hanson EW. Anticoagulation and elective surgery. N Engl J Med. 1997;337(13): 939; author reply 939-40.
8.
Shalaby A, Mohiuddin SM. Anticoagulation and elective surgery. N Engl J Med. 1997;337(13): 939; author reply 939-40.
9.
Spandorfer J, Merli G. Anticoagulation and elective surgery. N Engl J Med. 1997;337(13): 938-939; author reply 939-40.
10.
Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl): 204S-233S.
Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287(7): 324-327.
13.
Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J. 1979;97(2): 155-158.
14.
Hull RD, Raskob GE, Rosenbloom D, et al.Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322(18): 1260-1264.
15.
Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318(18): 1162-1173.
16.
Levine MN, Hirsh J, Gent M, et al.Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991;114(7): 545-551.
17.
Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78(9): 2337-2343.
18.
Treiman RL, Cossman DV, Foran RF, Levin PM, Cohen JL, Wagner WH. The influence of neutralizing heparin after carotid endarterectomy on postoperative stroke and wound hematoma. J Vasc Surg. 1990;12(4): 440-445; discussion 445-6.
19.
Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl): 287S-310S.
20.
Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164(12): 1319-1326.
21.
Kovacs MJ, Kearon C, Rodger M, et al.Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110(12): 1658-1663.
22.
Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001;119(1 Suppl): 220S-227S.
23.
Salem DN, Stein PD, Al-Ahmad A, et al.Antithrombotic therapy in valvular heart disease—native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl): 457S-482S.
24.
Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154): 717-719.
25.
Steward DJ, Haining RL, Henne KR, et al.Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997;7(5): 361-367.
26.
Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol. 1999;84(4): 478-480, A10.
27.
Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J.Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart. 2003;89(5): 527-530.
28.
Eckman MH. Anticoagulation during non-cardiac surgical operations in patients with prosthetic valves. In: Butchart EG, Bodnar E, ed. Thrombosis, Embolism, and Bleeding. London: ICR; 1992.
